Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZBED5 antisense RNA 1 (ZBED5-AS1) is a long noncoding RNA transcribed antisense to the ZBED5 gene, a zinc-finger transcription factor[1][2][5]. ZBED5-AS1 acts as a cis-acting regulatory RNA, modulating gene expression without encoding a protein[1][5]. Its molecular role is largely uncharacterized, but functional studies reveal it promotes cell proliferation, migration, invasion, and inhibits apoptosis in lung adenocarcinoma cells by activating the ZNF146/ATR/Chk1 signaling axis and inducing the epithelial–mesenchymal transition (EMT)[4]. ZBED5-AS1 is upregulated in lung adenocarcinoma tissues and associated with aggressive tumor features such as elevated serum LDH and D-dimer levels, indicating a malignant phenotype[4]. Its expression is transferred via cancer-derived exosomes, promoting intercellular communication and tumor progression[4]. There are no known drugs targeting ZBED5-AS1 and no reported direct safety concerns from its modulation, though its functional importance in cancer biology suggests potential therapeutic interest[2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZBED5 antisense RNA 1 (ZBED5-AS1).